Clinical Trial

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

Study acronym: SmokeyFlu
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-17; most recent amendment 2026-04-24.
Status change: Suspended → Recruiting 2026-04-24
Status change: Not Yet Recruiting → Suspended 2025-06-16
Trial Details
NCT Number NCT06841913
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)
Conditions Smoke Exposure, Influenza
Enrollment 112 participants
Start Date 2025-09-26
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30